65340-71-8

Basic information

• Product Name: 8-BROMO-4-CHLOROQUINOLINE
• Synonyms: 4-CHLORO-8-BROMOQUINOLINE;8-BROMO-4-CHLOROQUINOLINE;BUTTPARK 89\01-01;8-Bromo-4-chloro-1-azanaphthalene
• CAS NO: 65340-71-8
• Molecular Formula: C9H5BrClN
• Molecular Weight: 242.5
• EINECS: -0
• Mol File: 65340-71-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 147-148 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• Boiling Point: 314.6 °C at 760 mmHg
• Flash Point: 144.1 °C
• Appearance: /
• Density: 1.673 g/cm³
• Vapor Pressure: 0.000853mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.91±0.30(Predicted)
• CAS DataBase Reference: 8-BROMO-4-CHLOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-4-CHLOROQUINOLINE(65340-71-8)
• EPA Substance Registry System: 8-BROMO-4-CHLOROQUINOLINE(65340-71-8)

Safety Data

• Hazard Codes: T
• Statements: 25-41
• Safety Statements: 26-39-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 65340-71-8(Hazardous Substances Data)

Usage

Chemical Properties

yellow powder

InChI:InChI=1/C9H5BrClN/c10-7-3-1-2-6-8(11)4-5-12-9(6)7/h1-5H

Upstream product

• 615-36-1 2-bromoaniline 
• 57798-00-2 8-bromo-1,4-dihydroquinolin-4-one 
• 90279-39-3 8-bromoquinoline N-oxide 
• 57798-00-2 4-hydroxy-8-bromoquinoline 

Downstream Products

• 874831-36-4 C₁₀H₈BrNO 

Relevant articles and documents

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

Compound serving as IRAK inhibitor

The present invention relates to a compound suitable for the treatment of cancer and inflammatory diseases associated with interleukin-1 receptor associated kinase (IRAK), particularly relates to a compound serving as an IRAK4 inhibitor and a preparation

Synthesis, molecular docking study, and evaluation of the antiproliferative action of a new group of propargylthio- and propargylselenoquinolines

This study describes the synthesis of a new group of halogenopropargylthio- , dipropargylthio-, and halogenopropargylseleno-quinoline derivatives. The ability of all of the synthesized compounds to inhibit the proliferation of the T-47D, MCF-7, MDA-MB-231, and SNB-19 cell lines was determined with the WST-1 assay. The normal fibroblast cell line (HFF-1) was used as a control. The cytotoxic properties of these new, modified propargylquinoline derivatives were comparable to those of cisplatin. The most active compounds, 4,7-dipropargylthiquinoline (8b) and 7-chloro-4-propargylselenoquinoline (5b), were docked into the binding site of human CYP1A1 and CYP1B1. Our data indicate that these derivatives may present promising chemotherapeutic agents, possibly targeting CYP1s pathway.